Premium
Quetiapine, an Atypical Antipsychotic
Author(s) -
Goren Jessica L.,
Levin Gary M.
Publication year - 1998
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1998.tb03136.x
Subject(s) - quetiapine , olanzapine , clozapine , risperidone , atypical antipsychotic , dopamine receptor d2 , schizophrenia (object oriented programming) , antipsychotic , antipsychotic agent , pharmacology , medicine , psychology , typical antipsychotic , dopamine , psychiatry
The discovery of antipsychotic agents in the 1950s revolutionized the treatment of schizophrenia. A large body of evidence supports the dopamine D 2 receptor antagonist's efficacy in the treatment of psychotic symptoms. However, the advent of newer agents seems to point to a more complex interaction of neurotransmission in the pathophysiology of schizophrenia. In fact, a defining characteristic of atypical agents is a higher ratio of serotonin (5HT 2 ) receptor blockade to D 2 receptor blockade. Clozapine was the first atypical agent to be introduced; it was followed by risperidone, olanzapine, and now quetiapine, which is a dibenzothiazepine derivative structurally related to clozapine and olanzapine.